Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment DOI Open Access
C. Duta,

Corina Muscurel,

Carmen Beatrice Dogaru

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1516 - 1516

Published: Feb. 11, 2025

This review explores the promising potential of repurposing type 2 diabetes (T2D) medications for treatment Parkinson's disease (PD), highlighting shared pathophysiological mechanisms between these two age-related conditions, such as oxidative stress, mitochondrial dysfunction, and ferroptosis. The overlap suggests that existing drugs could target common pathways involved in both conditions. Specifically, discusses how T2D medications, including metformin (Met), peroxisome-proliferator-activated receptor gamma (PPAR-γ) agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, incretins, dipeptidyl-peptidase 4 (DPP-4) can improve function, reduce neuroinflammation potentially inhibit connection ferroptosis treatments, medication, are only beginning to be explored. limited data attributed also complexity fact specific role pathogenesis has not been a primary focus until recent. Despite preclinical evidence, clinical findings mixed, underscoring need further research elucidate drugs' roles neurodegeneration. Repurposing have well-established safety profiles significantly time cost associated with drug development offer more comprehensive approach managing compared treatments targeting single mechanism.

Language: Английский

Understanding Selenoproteins: Structural insights, biological functions and transformative applications in therapeutics DOI

Bhairav Prasad,

Akanksha Akanksha,

Palki Sahib Kaur

et al.

Process Biochemistry, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Selenoproteins: Zoom-In to Their Metal-Binding Properties in Neurodegenerative Diseases DOI Open Access
C. Duta,

Corina Muscurel,

Carmen Beatrice Dogaru

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1305 - 1305

Published: Feb. 3, 2025

Selenoproteins contain selenium (Se), which is included in the 21st proteinogenic amino acid selenocysteine (Sec). Selenium (Se) an essential trace element that exerts its biological actions mainly through selenoproteins. have crucial roles maintaining healthy brain activity. At same time, brain-function-associated selenoproteins may also be involved neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s (PD). The GPx4 (glutathione peroxidase 4), GPx1 1), SELENOP (selenoprotein P), SELENOK K), SELENOS S), SELENOW W), SELENOT T) are highly expressed, specifically AD-related regions being closely correlated to function. Only a few selenoproteins, mentioned above (especially SELENOP), can bind transition heavy metals. Metal ion homeostasis accomplishes vital physiological function of brain. Dyshomeostasis these metals induces entertains diseases. In this review, we described some proposed established mechanisms underlying properties above-mentioned having characteristic feature binding or

Language: Английский

Citations

0
Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment DOI Open Access
C. Duta,

Corina Muscurel,

Carmen Beatrice Dogaru

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1516 - 1516

Published: Feb. 11, 2025

This review explores the promising potential of repurposing type 2 diabetes (T2D) medications for treatment Parkinson's disease (PD), highlighting shared pathophysiological mechanisms between these two age-related conditions, such as oxidative stress, mitochondrial dysfunction, and ferroptosis. The overlap suggests that existing drugs could target common pathways involved in both conditions. Specifically, discusses how T2D medications, including metformin (Met), peroxisome-proliferator-activated receptor gamma (PPAR-γ) agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, incretins, dipeptidyl-peptidase 4 (DPP-4) can improve function, reduce neuroinflammation potentially inhibit connection ferroptosis treatments, medication, are only beginning to be explored. limited data attributed also complexity fact specific role pathogenesis has not been a primary focus until recent. Despite preclinical evidence, clinical findings mixed, underscoring need further research elucidate drugs' roles neurodegeneration. Repurposing have well-established safety profiles significantly time cost associated with drug development offer more comprehensive approach managing compared treatments targeting single mechanism.

Language: Английский

Citations

0